Senti Bio has received the green light from the FDA for SENTI-202, aimed at addressing recurring or stubborn blood cancers, such as Acute Myeloid Leukemia.

MR(Mineralocorticoid Receptor) antagonists are drugs that block the mineralocorticoid receptor, aiding in the treatment of hypertension and heart failure.

Tyra Biosciences successfully administered the inaugural dose of TYRA-200 to a patient and shared encouraging progress on their TYRA-300 development.

Protein palmitoylation is a post-translational modification that involves the addition of a 16-carbon saturated fatty acid, typically palmitate (C16:0), to cysteine residues within target proteins.

U.S. health authorities expedite assessment of Patritumab Deruxtecan for select cases of advanced or widespread EGFR-altered Non-Small Cell Lung Cancer after first treatments.

Histamine receptor antagonists are drugs that block histamine action, relieving allergic reactions.

Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. have announced obtaining approval from Japan's Ministry of Health, Labour and Welfare to commercially distribute Rituxan®.

Ubiquitination is a process that involves adding a protein called ubiquitin to a substrate protein.

Mineralys Therapeutics Reports Initial Participant Receives Dose in Start-HTN, Their Second Major Study of Lorundrostat Aimed at Hypertension Management.

H2 receptor antagonists are drugs that inhibit histamine action in the stomach, reducing acid production.

Jazz Pharmaceuticals plc announced early results from its Phase 2 trial evaluating the efficacy and safety of JZP150, a selective FAAH enzyme inhibitor, in adults with PTSD.

Drug delivery can be significantly affected by the pH of the environment in which it occurs.